Deep Longevity, Ltd.

Originally incubated by Insilico Medicine, Deep Longevity was acquired on December 14, 2020 by Regent Pacific Group Limited (SEHK:0575.HK), a specialist health care, wellness, and life sciences investment group. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, enabling physicians to make better decisions on the interventions that may slow down or reverse the aging processes. Deep Longevity developed the Longevity as a Service (LaaS) solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. http://longevity.ai